Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Introduction to psychosexual medicine.

Evans DT.

BMJ Sex Reprod Health. 2019 Oct 11. pii: bmjsrh-2019-200453. doi: 10.1136/bmjsrh-2019-200453. [Epub ahead of print] No abstract available.

PMID:
31604802
2.

Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques.

Gonzalez-Nieto L, Castro IM, Bischof GF, Shin YC, Ricciardi MJ, Bailey VK, Dang CM, Pedreño-Lopez N, Magnani DM, Ejima K, Allison DB, Gil HM, Evans DT, Rakasz EG, Lifson JD, Desrosiers RC, Martins MA.

PLoS Pathog. 2019 Sep 30;15(9):e1008015. doi: 10.1371/journal.ppat.1008015. eCollection 2019 Sep.

3.

Seven-day ischaemic preconditioning improves muscle efficiency during cycling.

Jeffries O, Evans DT, Waldron M, Coussens A, Patterson SD.

J Sports Sci. 2019 Sep 9:1-8. doi: 10.1080/02640414.2019.1664537. [Epub ahead of print]

PMID:
31500494
4.

Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIVsmm/mac Envelope Glycoprotein Uncouple Antibody-Dependent Cellular Cytotoxicity from Neutralization.

von Bredow B, Andrabi R, Grunst M, Grandea AG 3rd, Le K, Song G, Berndsen ZT, Porter K, Pallesen J, Ward AB, Burton DR, Evans DT.

MBio. 2019 Jul 2;10(4). pii: e01255-19. doi: 10.1128/mBio.01255-19.

5.

A SNP of lncRNA gives HIV-1 a boost.

Janaka SK, Evans DT.

Nat Immunol. 2019 Jul;20(7):778-780. doi: 10.1038/s41590-019-0422-1. No abstract available.

PMID:
31209401
6.

The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation.

Mediouni S, Kessing CF, Jablonski JA, Thenin-Houssier S, Clementz M, Kovach MD, Mousseau G, de Vera IMS, Li C, Kojetin DJ, Evans DT, Valente ST.

FASEB J. 2019 Jul;33(7):8280-8293. doi: 10.1096/fj.201801165R. Epub 2019 Apr 25.

PMID:
31021670
7.

Antibody-Induced Internalization of HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env.

Anand SP, Grover JR, Tolbert WD, Prévost J, Richard J, Ding S, Baril S, Medjahed H, Evans DT, Pazgier M, Mothes W, Finzi A.

J Virol. 2019 May 15;93(11). pii: e00293-19. doi: 10.1128/JVI.00293-19. Print 2019 Jun 1.

PMID:
30894474
8.

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.

Pauthner MG, Nkolola JP, Havenar-Daughton C, Murrell B, Reiss SM, Bastidas R, Prévost J, Nedellec R, von Bredow B, Abbink P, Cottrell CA, Kulp DW, Tokatlian T, Nogal B, Bianchi M, Li H, Lee JH, Butera ST, Evans DT, Hangartner L, Finzi A, Wilson IA, Wyatt RT, Irvine DJ, Schief WR, Ward AB, Sanders RW, Crotty S, Shaw GM, Barouch DH, Burton DR.

Immunity. 2019 Jan 15;50(1):241-252.e6. doi: 10.1016/j.immuni.2018.11.011. Epub 2018 Dec 11.

9.

Diversification of Bw4 Specificity and Recognition of a Nonclassical MHC Class I Molecule Implicated in Maternal-Fetal Tolerance by Killer Cell Ig-like Receptors of the Rhesus Macaque.

Banerjee P, Ries M, Janaka SK, Grandea AG 3rd, Wiseman R, O'Connor DH, Golos TG, Evans DT.

J Immunol. 2018 Nov 1;201(9):2776-2786. doi: 10.4049/jimmunol.1800494. Epub 2018 Sep 19.

PMID:
30232137
10.

Polymorphisms in Rhesus Macaque Tetherin Are Associated with Differences in Acute Viremia in Simian Immunodeficiency Virus Δnef-Infected Animals.

Janaka SK, Tavakoli-Tameh A, Neidermyer WJ Jr, Serra-Moreno R, Hoxie JA, Desrosiers RC, Johnson RP, Lifson JD, Wolinsky SM, Evans DT.

J Virol. 2018 Oct 29;92(22). pii: e00542-18. doi: 10.1128/JVI.00542-18. Print 2018 Nov 15.

11.

Current approaches to HIV prevention, treatment and care.

Evans DT, Dukes M.

Nurs Stand. 2018 Nov 1;33(8):45-52. doi: 10.7748/ns.2018.e11046. Epub 2018 Jun 20.

PMID:
29923694
12.

Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.

Martins MA, Tully DC, Pedreño-Lopez N, von Bredow B, Pauthner MG, Shin YC, Yuan M, Lima NS, Bean DJ, Gonzalez-Nieto L, Domingues A, Gutman MJ, Maxwell HS, Magnani DM, Ricciardi MJ, Bailey VK, Altman JD, Burton DR, Ejima K, Allison DB, Evans DT, Rakasz EG, Parks CL, Bonaldo MC, Capuano S 3rd, Lifson JD, Desrosiers RC, Allen TM, Watkins DI.

J Virol. 2018 Jul 31;92(16). pii: e00690-18. doi: 10.1128/JVI.00690-18. Print 2018 Aug 15.

13.

Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses.

Richard J, Prévost J, Baxter AE, von Bredow B, Ding S, Medjahed H, Delgado GG, Brassard N, Stürzel CM, Kirchhoff F, Hahn BH, Parsons MS, Kaufmann DE, Evans DT, Finzi A.

MBio. 2018 Mar 20;9(2). pii: e00358-18. doi: 10.1128/mBio.00358-18.

14.

Maintenance of AP-2-Dependent Functional Activities of Nef Restricts Pathways of Immune Escape from CD8 T Lymphocyte Responses.

Schouest B, Weiler AM, Janaka SK, Myers TA, Das A, Wilder SC, Furlott J, Baddoo M, Flemington EK, Rakasz EG, Evans DT, Friedrich TC, Maness NJ.

J Virol. 2018 Feb 12;92(5). pii: e01822-17. doi: 10.1128/JVI.01822-17. Print 2018 Mar 1.

15.

Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques.

Martins MA, Shin YC, Gonzalez-Nieto L, Domingues A, Gutman MJ, Maxwell HS, Castro I, Magnani DM, Ricciardi M, Pedreño-Lopez N, Bailey V, Betancourt D, Altman JD, Pauthner M, Burton DR, von Bredow B, Evans DT, Yuan M, Parks CL, Ejima K, Allison DB, Rakasz E, Barber GN, Capuano S 3rd, Lifson JD, Desrosiers RC, Watkins DI.

PLoS Pathog. 2017 Jul 21;13(7):e1006529. doi: 10.1371/journal.ppat.1006529. eCollection 2017 Jul.

16.

KIR3DL01 upregulation on gut natural killer cells in response to SIV infection of KIR- and MHC class I-defined rhesus macaques.

Ries M, Reynolds MR, Bashkueva K, Crosno K, Capuano S 3rd, Prall TM, Wiseman R, O'Connor DH, Rakasz EG, Uno H, Lifson JD, Evans DT.

PLoS Pathog. 2017 Jul 14;13(7):e1006506. doi: 10.1371/journal.ppat.1006506. eCollection 2017 Jul.

17.

BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH, Kaufmann DE, Smith AB 3rd, Sodroski J, Sauter D, Kirchhoff F, Gee K, Neil SJ, Evans DT, Finzi A.

J Virol. 2017 May 12;91(11). pii: e00219-17. doi: 10.1128/JVI.00219-17. Print 2017 Jun 1.

18.

Beyond Viral Neutralization.

Lewis GK, Pazgier M, Evans DT, Ferrari G, Bournazos S, Parsons MS, Bernard NF, Finzi A.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):760-764. doi: 10.1089/AID.2016.0299. Epub 2017 Feb 16. Review.

19.

Tetherin Antagonism by HIV-1 Group M Nef Proteins.

Arias JF, Colomer-Lluch M, von Bredow B, Greene JM, MacDonald J, O'Connor DH, Serra-Moreno R, Evans DT.

J Virol. 2016 Nov 14;90(23):10701-10714. doi: 10.1128/JVI.01465-16. Print 2016 Dec 1.

20.

OMIP-035: Functional analysis of natural killer cell subsets in macaques.

Weisgrau KL, Ries M, Pomplun N, Evans DT, Rakasz EG.

Cytometry A. 2016 Sep;89(9):799-802. doi: 10.1002/cyto.a.22932. Epub 2016 Aug 17.

21.

HLA-C Downmodulation by HIV-1 Vpu.

Barker E, Evans DT.

Cell Host Microbe. 2016 May 11;19(5):570-1. doi: 10.1016/j.chom.2016.04.023.

22.

Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT.

J Virol. 2016 Jun 10;90(13):6127-6139. doi: 10.1128/JVI.00347-16. Print 2016 Jul 1.

23.

Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa.

Hölzemer A, Thobakgale CF, Jimenez Cruz CA, Garcia-Beltran WF, Carlson JM, van Teijlingen NH, Mann JK, Jaggernath M, Kang SG, Körner C, Chung AW, Schafer JL, Evans DT, Alter G, Walker BD, Goulder PJ, Carrington M, Hartmann P, Pertel T, Zhou R, Ndung'u T, Altfeld M.

PLoS Med. 2015 Nov 17;12(11):e1001900; discussion e1001900. doi: 10.1371/journal.pmed.1001900. eCollection 2015 Nov.

24.

Suppression of a Natural Killer Cell Response by Simian Immunodeficiency Virus Peptides.

Schafer JL, Ries M, Guha N, Connole M, Colantonio AD, Wiertz EJ, Wilson NA, Kaur A, Evans DT.

PLoS Pathog. 2015 Sep 2;11(9):e1005145. doi: 10.1371/journal.ppat.1005145. eCollection 2015 Sep.

25.

The killer-cell immunoglobulin-like receptors of macaques.

Bimber BN, Evans DT.

Immunol Rev. 2015 Sep;267(1):246-58. doi: 10.1111/imr.12329. Review.

26.

Envelope Glycoprotein Internalization Protects Human and Simian Immunodeficiency Virus-Infected Cells from Antibody-Dependent Cell-Mediated Cytotoxicity.

von Bredow B, Arias JF, Heyer LN, Gardner MR, Farzan M, Rakasz EG, Evans DT.

J Virol. 2015 Oct;89(20):10648-55. doi: 10.1128/JVI.01911-15. Epub 2015 Aug 12.

27.

OMIP-028: activation panel for Rhesus macaque NK cell subsets.

Pomplun N, Weisgrau KL, Evans DT, Rakasz EG.

Cytometry A. 2015 Oct;87(10):890-3. doi: 10.1002/cyto.a.22727. Epub 2015 Jul 28. No abstract available.

28.

Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice.

Scull MA, Shi C, de Jong YP, Gerold G, Ries M, von Schaewen M, Donovan BM, Labitt RN, Horwitz JA, Gaska JM, Hrebikova G, Xiao JW, Flatley B, Fung C, Chiriboga L, Walker CM, Evans DT, Rice CM, Ploss A.

Hepatology. 2015 Jul;62(1):57-67. doi: 10.1002/hep.27773. Epub 2015 Apr 15.

29.

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES Jr, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M Jr, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M.

Nature. 2015 Mar 5;519(7541):87-91. doi: 10.1038/nature14264. Epub 2015 Feb 18.

30.

Tethering viral restriction to signal transduction.

Arias JF, Evans DT.

Cell Host Microbe. 2014 Sep 10;16(3):267-9. doi: 10.1016/j.chom.2014.08.013.

31.

Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.

Li Q, Zeng M, Duan L, Voss JE, Smith AJ, Pambuccian S, Shang L, Wietgrefe S, Southern PJ, Reilly CS, Skinner PJ, Zupancic ML, Carlis JV, Piatak M Jr, Waterman D, Reeves RK, Masek-Hammerman K, Derdeyn CA, Alpert MD, Evans DT, Kohler H, Müller S, Robinson J, Lifson JD, Burton DR, Johnson RP, Haase AT.

J Immunol. 2014 Sep 15;193(6):3113-25. doi: 10.4049/jimmunol.1400820. Epub 2014 Aug 18.

32.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, Janes H, Morris D, Fong Y, Edlefsen PT, Li F, Frahm N, Alpert MD, Prentice H, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Robb ML, O'Connell RJ, Haynes BF, Michael NL, Kim JH, McElrath MJ, Geraghty DE.

J Clin Invest. 2014 Sep;124(9):3879-90. doi: 10.1172/JCI75539. Epub 2014 Aug 8.

33.

Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function.

van Teijlingen NH, Hölzemer A, Körner C, García-Beltrán WF, Schafer JL, Fadda L, Suscovich TJ, Brander C, Carrington M, Evans DT, van Baarle D, Altfeld M.

AIDS. 2014 Jun 19;28(10):1399-408. doi: 10.1097/QAD.0000000000000284.

34.

Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.

Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, Rakasz EG, Evans DT.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6425-30. doi: 10.1073/pnas.1321507111. Epub 2014 Apr 14.

35.

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD.

Sci Transl Med. 2014 Mar 19;6(228):228ra39. doi: 10.1126/scitranslmed.3007730.

36.

KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeys.

Schafer JL, Colantonio AD, Neidermyer WJ, Dudley DM, Connole M, O'Connor DH, Evans DT.

J Immunol. 2014 Feb 15;192(4):1907-17. doi: 10.4049/jimmunol.1302883. Epub 2014 Jan 22.

37.

Teenage pregnancy and sexual health.

Hadley A, Evans DT.

Nurs Times. 2013 Nov 20-26;109(46):22, 25-7.

PMID:
24383309
38.

Promoting sexual health and wellbeing: the role of the nurse.

Evans DT.

Nurs Stand. 2013 Nov 6-12;28(10):53-7; quiz 60. doi: 10.7748/ns2013.11.28.10.53.e7654.

PMID:
24191835
39.

Tetherin upregulation in simian immunodeficiency virus-infected macaques.

Rahmberg AR, Neidermyer WJ Jr, Breed MW, Alvarez X, Midkiff CC, Piatak M Jr, Lifson JD, Evans DT.

J Virol. 2013 Dec;87(24):13917-21. doi: 10.1128/JVI.01757-13. Epub 2013 Oct 9.

40.

Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis.

Serra-Moreno R, Zimmermann K, Stern LJ, Evans DT.

PLoS Pathog. 2013;9(7):e1003487. doi: 10.1371/journal.ppat.1003487. Epub 2013 Jul 11.

41.

Nonhuman primate models in AIDS research.

Evans DT, Silvestri G.

Curr Opin HIV AIDS. 2013 Jul;8(4):255-61. doi: 10.1097/COH.0b013e328361cee8. Review.

42.

Animal models for HIV/AIDS research.

Hatziioannou T, Evans DT.

Nat Rev Microbiol. 2012 Dec;10(12):852-67. doi: 10.1038/nrmicro2911. Review.

43.

The restriction factors of human immunodeficiency virus.

Harris RS, Hultquist JF, Evans DT.

J Biol Chem. 2012 Nov 30;287(49):40875-83. doi: 10.1074/jbc.R112.416925. Epub 2012 Oct 5. Review.

44.

A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Alpert MD, Heyer LN, Williams DE, Harvey JD, Greenough T, Allhorn M, Evans DT.

J Virol. 2012 Nov;86(22):12039-52. doi: 10.1128/JVI.01650-12. Epub 2012 Aug 29.

45.

ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.

Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT.

PLoS Pathog. 2012;8(8):e1002890. doi: 10.1371/journal.ppat.1002890. Epub 2012 Aug 23.

46.

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF.

J Virol. 2012 Nov;86(21):11521-32. doi: 10.1128/JVI.01023-12. Epub 2012 Aug 15.

47.

Adaptation of human and simian immunodeficiency viruses for resistance to tetherin/BST-2.

Serra-Moreno R, Evans DT.

Curr HIV Res. 2012 Jun;10(4):277-82.

PMID:
22524175
48.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

49.

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR.

J Virol. 2012 Jun;86(11):6189-96. doi: 10.1128/JVI.00491-12. Epub 2012 Mar 28.

50.

A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, Poignard P, Hessell AJ, Burton DR.

J Virol. 2011 Oct;85(20):10572-81. doi: 10.1128/JVI.05541-11. Epub 2011 Aug 17.

Supplemental Content

Loading ...
Support Center